Busulfan, a bifunctional alkylating agent, has been used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). The aim of this study was to derive a novel once-daily intravenous (IV) busulfan dosing nomogram for pediatric patients undergoing HSCT using a population pharmacokinetic (PK) model. A population PK analysis was performed using 2183 busulfan concentrations in 137 pediatric patients (age: 0.6-22.2 years), who received IV busulfan once-daily for 4 days before undergoing HSCT. Based on the final population PK model, an optimal once-daily IV busulfan dosing nomogram was derived. The percentage of simulated patients achieving the daily target area under the concentration-time curve (AUC) by the new nomogram was compared with that by other busulfan dosing regimens including the FDA regimen, the EMA regimen, and the empirical once-daily regimen without therapeutic drug monitoring (TDM). A one-compartment open linear PK model incorporating patient's body surface area, age, dosing day, and aspartate aminotransferase as a significant covariate adequately described the concentration-time profiles of busulfan. An optimal dosing nomogram based on the PK model performed significantly better than the other dosing regimens, resulting in >60% of patients achieving the target AUC while the percentage of patients exceeding the toxic AUC level was kept <25% during the entire treatment period. A novel once-daily busulfan dosing nomogram for pediatric patients undergoing HSCT is useful for clinicians, particularly in a setting where TDM service is not readily available or to optimize the dose on day 1.
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| I N T R O D U C T I O N
Busulfan, a bifunctional alkylating agent, has been used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). 1 Busulfan has a narrow therapeutic window and its large interindividual variability can be reduced by intravenous administration. 2, 3 The systemic exposure to busulfan is well associated with clinical outcomes. For example, when given four times a day, a busulfan exposure <900 lMÁmin or 3.69 mgÁh/L, as assessed by the area under the concentration-time curve over the dosing interval (AUC tau ), increased the likelihood of graft failure and recurrence of disease. 4, 5 In contrast, a busulfan AUC tau >1500 lMÁmin or 6.16 mgÁh/L increased the frequency of hepatic and neurologic toxicities. [6] [7] [8] Due to its narrow therapeutic window, however, therapeutic drug monitoring (TDM) is still recommended for busulfan to optimize its dosing regimen. To support this notion, the TDM of busulfan reduced the toxicity of allogeneic HSCT preparative regimens.
9,10
The utility of busulfan TDM is more obvious in pediatric patients because their pharmacokinetic (PK) inter-individual variability (IIV) is much greater than that in adults. 11 The large inter-individual variability of busulfan PK in children, particularly clearance (CL), can be attributed to a wide range of body size indices in this population (e.g., actual body weight, ideal body weight, and body surface area). 11, 12 Furthermore, maturation factors such as postmenstrual or postnatal age should be also taken into account. Therefore, previous studies attempted to identify the most significant covariate for the PK parameters of busulfan in the pediatric population in an anticipation of developing a novel dosing nomogram, which might reduce the need for TDM. [13] [14] [15] [16] [17] However, it is still controversial which covariate is the most influential in explaining the variability of busulfan PK in children.
Conventionally, intravenous busulfan has been given four-times daily for four consecutive days. 1 More recently, however, comparable PK and clinical outcomes have been reported between 4-times and once-daily regimens in both adults and children. 2, 3, 18 Although less frequent administration is certainly more convenient, once-daily regimen of intravenous busulfan has been rarely used, particularly in children, because there has been no consensus as to which covariate the dosing nomogram should be based on.
Based on this understanding, the objectives of the present study were (1) to characterize the PK of once-daily intravenous busulfan, (2) to identify significant covariates that might affect the PK parameters of busulfan, and (3) to derive an optimal once-daily dosing nomogram for intravenous busulfan in pediatric patients undergoing HSCT. To this end, we performed a population PK analysis, coupled with simulation experiments for various busulfan dosing regimens in that population. 
| M E T H O D S

| Patients and treatments
| Model qualification
The medians of the PK parameters repeatedly fit using 1000 resampled bootstrap data sets were compared with the parameter estimates of the final PK model to evaluate its stability. Furthermore, the 95% confidence intervals (CIs) were constructed as the 2. ; (3) the empirical once-daily regimen without TDM, for which patients were assumed to receive the same once-daily dose for 4 days; and (4) an optimal nomogram-based regimen. To devise the optimal once-daily dosing nomogram, the empirical Bayes estimates of daily CL were obtained using the final population PK model in virtual patients. In the nomogram, age was categorized into nine groups (i.e., <1, 1-1.33, 1.33-1.67, 1.67-2, 2-3, 3-5, 5-7, 7-11, and !11 years), in each of which the estimates of daily CL were similar.
Then, a once-daily intravenous busulfan dose was the product of the BSA-normalized daily CL and the daily target AUC of 18.75 mgÁh/L.
| R E S U LTS
| Patient demographics
A total of 2183 samples obtained from 137 patients (70 males and 67 females) 0.6 to 22.2 years of age were available for PK evaluation (Supporting Information Table S1 ). 
| Population PK model
A one-compartment open linear model with proportional residual variability adequately described the observed concentration-time profiles of intravenous busulfan in subjects (Table 2) . IIVs for CL and volume of distribution (V) were included in the final PK model, while IOV was included only for CL. A covariance term between the IIVs of CL and V was also estimated in the final PK model. BSA, modeled using a power term, was a significant covariate for CL and V. In addition, age, AST and dosing day also improved the fit significantly when they were included as a covariate for CL. For example, the effect of maturation on the CL of busulfan was incorporated into the final PK model such that the typical adult CL value would be achieved approximately at 2.3 years (Supporting Information Figure S1 ). Furthermore, AST negatively affected busulfan CL; when AST was 93.0 IU/L, the CL of busulfan decreased to 97.1% of that for AST of 40 IU/L. When compared with day 1, the CL of busulfan on days 2, 3, and 4 was decreased by 5.5%, 13.1%, and 8.1%, respectively.
| Model qualification
The population and individual model-predicted busulfan concentrations versus the observed data were spread randomly around the line of identity, indicating that the data were well described by the model (Supporting Information Figure S2 ). Furthermore, the median parameter estimates obtained from the re-sampled bootstrap datasets were almost the same as the estimates obtained from the final population PK model using the original data set (Table 2 ). Likewise, the results of the pcVPCs showed that most of the observed concentrations were contained within the 5 th and 95 th prediction intervals of the simulated concentrations based on the final PK model (Supporting Information Figure S3 ). Collectively, the final PK model was robust, reliable, and adequate to describe the PK profiles of busulfan after it was intravenously administered once daily for 4 days in pediatric patients undergoing HSCT.
| Optimal once-daily busulfan dosing nomogram
An optimal dosing nomogram for busulfan was derived to attain the daily target AUC of 18.75 mgÁh/L based on patient's BSA, age, and dosing day ( Table 3 ). The effect of AST was not considered in the optimal dosing nomogram because its effect was relatively small. Compared with the empirical once-daily regimen, the optimal nomogram recommends an 0-19 mg/m 2 lower starting dose on day 1 for age !1 year, whereas the recommended dose for age <1 was similar between the two regimens.
| Comparison of dosing regimens
Overall, the TDM-supported empirical once-daily regimen, which is the current practice at Seoul National University Hospital, showed the best performance in attaining the target therapeutic AUC range for 4 days (Figure 1) . However, the initial dose of busulfan by this regimen still resulted in only 55% of patients achieving the target AUC range on day 1 while a relatively high percentage of patients ($30%) had an AUC falling in the toxic range ( Figure 1A ). When a fixed daily dose of busulfan was repeatedly administered for 4 days using the FDA regimen, EMA regimen, or the empirical once-daily regimen without TDM, the percentage of patients whose AUC fell within the subtherapeutic, target, or toxic AUC ranges markedly varied day by day (Figure 1B , C, and D, respectively). In contrast, the optimal nomogram-based regimen (Table 3) , which took into account patient's age, body surface area, and daily CL change, steadily resulted in >60% of patients achieving the target AUC while the percentage of patients exceeding the toxic AUC level was kept <25% during the entire treatment period ( Figure 1E ).
This target AUC-achieving performance of the optimal nomogram- based regimen was consistently seen in all age groups, whereas the other regimens led to variable and much smaller percentages of patients achieving the target AUC range (Supporting Information   Table S2 ).
| DISCUSSION
In this study, we have found that not only body habitus such as BSA as an anthropometric measure, but also age as a maturation factor should be taken into account when optimizing an intravenous busulfan dose in pediatric patients undergoing HSCT (Table 2 , Supporting Information Figure S1 ). Furthermore, we demonstrated that the clearance of busulfan decreases daily up to 13.1% on day 3 after intravenous administration (Table 2 ). Based on these findings, patient's BSA, age, and dosing day were incorporated into the optimal dosing regimen for busulfan (Table 3) , which performed significantly better in achieving the target therapeutic AUC than the other regimens such the FDA regimen, EMA regimen, or the empirical once-daily regimen without TDM (Figure 1 , Supporting Information Table S2 ). 
AST, aspartate transaminase; BSA, body surface area; CI, confidence interval as 2.5 th and 97.5 th percentiles derived from a bootstrap analysis of 1000 resampled datasets; CV, coefficient of variation; RSE, relative standard error. As seen in the present study, substantial daily changes in busulfan CL over the entire dosing period were noted previously. 23, 24 This indicates that not only the optimization of the initial busulfan dose, but its daily adjustment is necessary to obtain the best possible therapeutic results in pediatric patients undergoing HSCT. In this sense, TDMbased daily dosing may be still the best option. However, because busulfan is administered over a relatively short period of time (i.e., 4 days), a rapid dose adjustment based on the calculated CL can be challenging for many clinicians, particularly for those who are working in clinics or hospitals that do not provide prompt TDM service. In this case, the once-daily busulfan dosing nomogram, which incorporated daily CL, such as the one we proposed in the present study, can be a useful tool for maximizing the clinical efficacy of busulfan while reducing its toxicity.
Although an optimal initial dose of once-daily busulfan has been proposed several times using the results of population PK studies, [15] [16] [17] 25 few of them was based on pediatric patients or the number of included children was small. Therefore, the large sample size of pediatric patients included in our population PK analysis could contribute to devising a more reliable and robust dosing regimen for them as we demonstrated in terms of achieving the target AUC, particularly the initial dose on day 1 (Figure 1 , Supporting Information Table S2 ). Based on the optimal nomogram, the busulfan dose on day 1 should be reduced by 3-19 mg/m 2 for patients 1-11 years of age (Table 3) to lower the ; and E (the optimal nomogram, see Table 3 ). The subtherapeutic, target, and toxic AUC ranges were <15 mgÁh/L for each day or <60 mgÁh/L for 4 days, 15-22.5 mgÁh/L or 60-90 mgÁh/L for 4 days, and >22.5 mgÁh/L or >90 mgÁh/L for 4 days, respectively
percentage of patients whose AUC may fall in the toxic range as shown in Figure 1A .
The final population PK model adequately described the observed concentration-time profiles for once-daily busulfan dosing in pediatric patients undergoing HSCT. A one-compartment PK model has been reported previously for busulfan PK, 15, [25] [26] [27] [28] which was preferred to a two-compartment model in the present study as well based on the goodness-of-fit plots. The typical population estimates for CL (10.7 L/h) and V (43.8 L) in this study, standardized for an adult patient weighing 70 kg, were in accordance with those found in the literature. [26] [27] [28] Furthermore, the BSA-normalized CL of busulfan matured rather rapidly after birth, reaching the adult value at 2.3 years, which is comparable with the finding of another study that reported the busulfan CL reached 95% of the adult value at 2.5 postnatal years. 17 This agreement in the result strengthens the robustness of the final population PK model we developed, given that the structural model and size scaling factor in the previous study were different from those in the present study.
Because busulfan is mainly metabolized by the glutathione-S-transferase in the liver, 29 liver function could affect the CL of busulfan. To support this notion, AST was found to be a significant covariate for busulfan CL in this study. A previous study also reported that elevated ALT level reduced the CL of busulfan. 26 Nonetheless, AST was not taken into account in the optimal dosing nomogram in the present study, because the variation of busulfan CL by change in AST was relatively small compared with those caused by other significant covariates such as patient's BSA, age, and dosing day.
Iron overload is frequently seen in patients undergoing HSCT because of repeated blood transfusions, resulting in the increase in serum ferritin. Ferritin is a major intracellular iron storage protein, which hinders iron-catalyzed reactive oxygen species from being generated by chelating excess free iron. 30,31 Therefore, an elevated ferritin level may indicate a prior liver damage owing to iron-generated oxidative stress. 32 A previous study reported that an elevated ferritin level was associated with a high risk of hepatic veno-occlusive disease, which is a major toxicity of busulfan in children receiving a high-dose busulfan-containing regimen. 30 In this study, an inverse relationship between ferritin level and busulfan CL was found in the initial covariate search during the forward selection process, which was eventually removed from the final model because it failed to meet the backward elimination criteria (i.e., P-value .01). Therefore, the possibility of decreased busulfan CL by increased ferritin should be considered in clinical practice.
This study had some limitations. Although children with a wide range of age were included, the number of patients <1 year was small (i.e., n 5 5, 3.6%) and the minimum age was only 0.6 year. Because busulfan CL is maturated rapidly during 1 year after birth as shown in our model, further studies are warranted to refine the effect of age in neonates, which can enhance the target AUC-achieving performance of the dosing nomogram for busulfan in that population. Additionally, clinical outcomes such as graft failure and toxicity development should be investigated in a prospective manner to adequately investigate the whole utility of the proposed dosing nomogram.
In conclusion, a dosing nomogram for once-daily intravenous busulfan in pediatric patients undergoing HSCT, which incorporated patient's BSA, age, and dosing day, was successfully developed using a population PK model. The nomogram performed better than the other regimens in achieving the therapeutic target AUC, which can be useful for clinicians, particularly in a setting where TDM service is not readily available or to optimize the initial daily dose on day 1.
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